RxDoctor Payments Data

Jose Mena Pasquel, MD

Nephrology · Shelby, NCNPI 1275053217

Payments from drug & device makers

$2,771in general payments, 2019–2025

Across 149 payments — averaging $18.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$605
  • Calliditas Therapeutics US Inc.$518
  • Travere Therapeutics, Inc.$319
  • Otsuka America Pharmaceutical, Inc.$303
  • Akebia Therapeutics Inc$205
  • Bayer$164
  • plus $658 from 13 others

What the payments were for

  • Food & beverage$2,64595%
  • Education$1265%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,771 in reported general payments places this provider in the 60th percentile of 366 nephrology providers in North Carolina.

See all nephrology providers in North Carolina

Medicare billing

Part B allowed, 2024
$235,076
Medicare patients
546
Services billed
2,230

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol54$31,323
VeltassaPatiromer Calcium Sorbitex18$13,990
Sevelamer Carbonate62$6,063
Calcium Acetate47$5,320
ProsolParenteral Amino Acid 20% No.116$2,271
Torsemide61$1,243
Potassium Chloride19$1,024
Losartan Potassium133$781
Midodrine Hcl12$555
Chlorthalidone54$518
Hydralazine Hcl49$409
Lisinopril83$378
Amlodipine Besylate76$272
Nifedipine ErNifedipine13$241
Furosemide46$187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$605$31,32354 claims
ANI Pharmaceuticals, Inc.Valsartan$64$12821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 366 nephrology providers in North Carolina.

Other nephrology in Shelby

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →